Literature DB >> 22827245

Mucosal immunity and nasal influenza vaccination.

Markus A Rose1, Stefan Zielen, Ulrich Baumann.   

Abstract

Influenza remains a threat to public health, with immunization being a suitable method of infection prevention and control. Our understanding of the immunological regulations at the mucosa, antigen processing and presentation, and B-cell activation has improved, enabling research and targeted induction of immune responses at the site of antigen delivery. Nasal influenza immunization has distinct features compared with intramuscular vaccines, providing protection at the pathogen's entry site, higher levels of mucosal antibodies, cross-protection and needle-free application. This review summarizes our knowledge about mucosal immunity and the experience from clinical trials on the impact and safety of nasal influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827245     DOI: 10.1586/erv.12.31

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  38 in total

1.  CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.

Authors:  Y Yin; T Qin; X Wang; J Lin; Q Yu; Q Yang
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

Review 2.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Mucosal immunization in perspective.

Authors:  Markus A Rose
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

5.  CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa.

Authors:  Tao Qin; Yinyan Yin; Qinghua Yu; Lulu Huang; Xiaoqing Wang; Jian Lin; Qian Yang
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

Review 6.  Mucosal vaccines against respiratory syncytial virus.

Authors:  Kejian Yang; Steven M Varga
Journal:  Curr Opin Virol       Date:  2014-04-29       Impact factor: 7.090

7.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

8.  Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.

Authors:  Hui Wu; Yuanyuan Bao; Xiang Wang; Dongming Zhou; Wenzhe Wu
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

9.  Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.

Authors:  Hartinio N Nahampun; Brad Bosworth; Joan Cunnick; Mark Mogler; Kan Wang
Journal:  Plant Cell Rep       Date:  2015-02-13       Impact factor: 4.570

10.  H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.

Authors:  Tao Qin; Yinyan Yin; Lulu Huang; Qinghua Yu; Qian Yang
Journal:  Clin Vaccine Immunol       Date:  2015-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.